Wolverine Trading
PGNX

Wolverine Trading’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Wolverine Trading’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,938
Closed -$96K – 5665
2019
Q4 		$96K Sell
18,938
-4,146
-18% -$21.9K ﹤0.01% 4299
2019
Q3 		$121K Buy
23,084
+7,496
+48% +$37.4K ﹤0.01% 3796
2019
Q2 		$96K Sell
15,588
-4,619
-23% -$22.3K ﹤0.01% 4027
2019
Q1 		$94K Buy
20,207
+5,621
+39% +$25.4K ﹤0.01% 4165
2018
Q4 		$59K Sell
14,586
-1,491
-9% -$7.59K ﹤0.01% 4129
2018
Q3 		$101K Buy
+16,077
New +$123K ﹤0.01% 4544
2018
Q1 		– Sell
-21,114
Closed -$140K – 6162
2017
Q4 		$126K Buy
+21,114
New +$128K ﹤0.01% 4372
2017
Q3 		– Sell
-21,844
Closed -$139K – 5343
2017
Q2 		$152K Buy
+21,844
New +$161K ﹤0.01% 3742
2016
Q4 		– Sell
-10,668
Closed -$78.9K – 5470
2016
Q3 		$61K Buy
+10,668
New +$64.5K ﹤0.01% 4360

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wolverine Trading's PGNX Position: Q1 2020 in Review

Wolverine Trading sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 18,938 shares — an estimated $96K sold.

Wolverine Trading first reported a position in PGNX in Q3 2016 and held it in 9 quarters. The position peaked at $152K in Q2 2017. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Wolverine Trading reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Wolverine Trading sold 18,938 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $96K.
  • Wolverine Trading first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 9 quarters.
  • Wolverine Trading's Progenics Pharmaceuticals Inc position peaked at $152K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Wolverine Trading's 13F filing for Q1 2020, filed 11 May 2020.